Wall Street brokerages forecast that BioDelivery Sciences International, Inc. (NASDAQ:BDSI) will report sales of $9.91 million for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for BioDelivery Sciences International’s earnings. The lowest sales estimate is $8.99 million and the highest is $10.93 million. BioDelivery Sciences International reported sales of $3.93 million during the same quarter last year, which indicates a positive year over year growth rate of 152.2%. The business is scheduled to report its next earnings report on Friday, March 16th.
On average, analysts expect that BioDelivery Sciences International will report full year sales of $9.91 million for the current year, with estimates ranging from $58.47 million to $64.10 million. For the next year, analysts forecast that the company will report sales of $50.45 million per share, with estimates ranging from $42.70 million to $66.90 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that follow BioDelivery Sciences International.
BioDelivery Sciences International (NASDAQ:BDSI) last released its earnings results on Thursday, November 9th. The specialty pharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.22) by $0.01. BioDelivery Sciences International had a net margin of 10.40% and a return on equity of 33.83%. The firm had revenue of $11.25 million during the quarter, compared to analyst estimates of $9.40 million. During the same period last year, the business earned ($0.30) earnings per share. The business’s revenue was up 215.1% on a year-over-year basis.
A number of hedge funds and other institutional investors have recently made changes to their positions in BDSI. Royce & Associates LP purchased a new position in BioDelivery Sciences International in the 3rd quarter worth approximately $3,814,000. Stonepine Capital Management LLC raised its holdings in BioDelivery Sciences International by 22.2% in the 2nd quarter. Stonepine Capital Management LLC now owns 3,477,673 shares of the specialty pharmaceutical company’s stock worth $9,737,000 after acquiring an additional 632,853 shares during the last quarter. EAM Investors LLC purchased a new position in BioDelivery Sciences International in the 2nd quarter worth approximately $1,348,000. GSA Capital Partners LLP raised its holdings in BioDelivery Sciences International by 10.1% in the 2nd quarter. GSA Capital Partners LLP now owns 488,767 shares of the specialty pharmaceutical company’s stock worth $1,369,000 after acquiring an additional 44,700 shares during the last quarter. Finally, JPMorgan Chase & Co. purchased a new position in BioDelivery Sciences International in the 3rd quarter worth approximately $116,000. Institutional investors own 44.08% of the company’s stock.
BioDelivery Sciences International (NASDAQ BDSI) opened at $2.85 on Tuesday. BioDelivery Sciences International has a 1-year low of $1.55 and a 1-year high of $3.60. The stock has a market cap of $159.27, a P/E ratio of 31.67 and a beta of 0.74. The company has a current ratio of 1.28, a quick ratio of 1.07 and a debt-to-equity ratio of 1.89.
TRADEMARK VIOLATION WARNING: “$9.91 Million in Sales Expected for BioDelivery Sciences International, Inc. (BDSI) This Quarter” was first posted by BBNS and is the sole property of of BBNS. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://baseballnewssource.com/markets/9-91-million-in-sales-expected-for-biodelivery-sciences-international-inc-bdsi-this-quarter/1819522.html.
About BioDelivery Sciences International
BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.